<DOC>
	<DOCNO>NCT02482311</DOCNO>
	<brief_summary>This open-label , multi-centre , Phase Ib study AZD1775 design assess safety , tolerability , pharmacokinetics , anti-tumour activity AZD1775 monotherapy patient advance solid tumour .</brief_summary>
	<brief_title>Safety , Tolerance , PK , Anti-tumour Activity AZD1775 Monotherapy Patients With Advanced Solid Tumours</brief_title>
	<detailed_description>This study conduct two part , designate Parts A B . Part A safety lead-in consist cohort approximately 12 patient advance solid tumour . Part B expansion cohort investigate AZD1775 monotherapy advance tumour type molecular biomarkers interest . The tumour type evaluate : 1 ) ovarian cancer ( BRCA1/2 mutation [ PARP-failures ] ) , 2 ) ovarian cancer ( BRCA wild-type ) three prior line treatment , 3 ) triple negative breast cancer ( TNBC ) , 4 ) small-cell lung cancer ( SCLC ) .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>1 . Age ≥18 2 . Previous chemotherapy recurrent metastatic disease . 3 . Measurable disease require Part B expansion cohort accord RECIST v1.1 criterion . 4 . Radiation therapy complete least 7 day prior start study treatment patient must recover acute adverse effect . 5 . ECOG Performance Status ( PS ) score 01 . 6 . Baseline laboratory value follow : 1 . ANC ≥1500/μL 2 . Hgb ≥9 g/dL 3 . Platelets ≥100,000/μL 4 . ALT AST ≤3 x ULN ≤5 x ULN know hepatic metastasis . 5 . Serum bilirubin WNL ≤1.5 x ULN patient liver metastasis ; total bilirubin ≤3.0 x ULN direct bilirubin WNL patient well document Gilbert 's Syndrome . 6 . Serum creatinine ≤1.5 x ULN calculate creatinine clearance ( CrCl ) ≥45 mL/min CockcroftGault method . 7 . Negative serum urine pregnancy test within 3 day prior start study treatment . 8 . Fertile male patient willing use least one medically acceptable form birth control duration study 2 week treatment stop . 9 . Predicted life expectancy ≥12 week . Inclusion Criteria Specific Part A : 1 . Histologically cytologically document , locally advanced metastatic solid tumour , exclude lymphoma , standard therapy exist proven ineffective intolerable . 2 . Has agree collection archival tumour tissue recent tumour biopsy tissue , take routine clinical purpose baseline archival tissue available , molecular biomarker analysis . Inclusion Criteria Specific Part B : 1 . Ovarian cancer define histologically confirm diagnosis epithelial ovarian , fallopian tube , primary peritoneal cancer refractory standard therapy standard therapy exists . Confirmed BRCA1 BRCA2 mutation prior test . Patient progress receive and/or follow treatment PARPinhibitor advance disease ( recurrent metastatic . 2 . Ovarian cancer confirm BRCA wildtype prior test . 3 . Triplenegative breast cancer ( TNBC ) define histologically confirm diagnosis breast cancer must receive least 1 chemotherapycontaining regimen advance disease ( recurrent metastatic ) . Tumour must triplenegative , define minimal expression estrogen progesterone receptor [ &lt; 10 % cell positive immunohistochemistry ( IHC ) ] , minimal expression HER2 ( IHC stain 0 1+ FISH ) . 4 . Smallcell lung cancer ( SCLC ) define histologically confirm diagnosis SCLC must receive least 1 chemotherapycontaining regimen advance disease ( recurrent metastatic ) . 1 . Any chemotherapy within 3 week first dose AZD1775 , except hormonal therapy refractory cohort . 2 . Use study drug ≤21 day 5 halflives , whichever short . 3 . Major surgical procedure ≤28 day , minor procedure ≤7 day . 4 . Grade &gt; 1 toxicity prior therapy ( except alopecia anorexia ) . 5 . CNS disease neurologically stable , treated brain metastasis . 6 . Prescription nonprescription drug product know sensitive CYP3A4 substrates CYP3A4 substrate narrow therapeutic index , moderate strong inhibitors/inducers CYP3A4 discontinue two week prior Day 1 dose withheld throughout study 2 week last dose study drug . 7 . NYHA ≥ Class 2 . 8 . Mean resting correct QT interval ( QTc ) ≥450 msec male ≥470 msec female . 9 . Pregnant lactating . 10 . Serious active infection , serious underlie medical condition . 12 . Presence active invasive cancer . 13 . Psychological , familial , sociological , geographical condition permit compliance protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>AZD1775</keyword>
	<keyword>Ovarian cancer ( BRCA1/2 mutation )</keyword>
	<keyword>Ovarian cancer ( PARP-failure )</keyword>
	<keyword>Triple negative breast cancer ( TNBC )</keyword>
	<keyword>Small-cell lung cancer ( SCLC )</keyword>
	<keyword>Solid tumour</keyword>
</DOC>